First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
This study is a single-arm, open-lable, single-center phase II clinical trial for patients with advanced or metastatic pleural mesothelioma. The aim of this study was to observe and evaluate the efficacy and safety of Sintilimab combined with Anlotinib hydrochloride and platinum-containing dual-agent chemotherapy as first-line therapy in malignant pleural mesothelioma.
Mesothelioma, Malignant|Mesothelioma, Malignant Pleural|Mesothelioma Malignant Advanced
DRUG: Sintilimab+Anlotinib+Pemetrexed+Cisplatin
ORR, Objective Response Rate（ORR）according to mRECIST 1.1 standard, 6 months after the final enrollment
DOR, Duration of remission, 24 months|DCR, Disease Control Rate, 24 months|PFS, Progression Free Survival, 24 months|OS, Overall Survival, 24 months|AE, Adverse event, 24 months|SAE, Incidence and Severity of Serious Adverse Event, 24 months|Lab indicators, Abnormal values of laboratory indicators, 24 months
Patients with advanced or metastatic (stage IIIB or IV) pleural mesothelioma who had not received previous systemic therapy were screened for eligible subjects to be eligible for enrollment after signing an written informed consent to receive Sintilimab combined with Anlotinib hydrochloride and platinum-containing dual-agent chemotherapy until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other antineoplastic therapy, death or other situations for which protocol specified treatment should be discontinued (whichever occurs first). The maximum duration of treatment with Sintilimab is 24 months (in general).